For instance, cutaneous skin melanoma cells bearing BRAFV 600E mutation that respond positively to Vemurafenib, the first BRAF kinase inhibitor approved to treat metastatic melanoma, progress to resistant cells (Bollag et al., 2012; Sullivan and Flaherty, 2013). Here, BRAF is linked to cutaneous melanoma.